Free Trial

Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

-0.12 (-2.80%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
120,548 shs
Average Volume
168,341 shs
Market Capitalization
$210.12 million
P/E Ratio
Dividend Yield
Price Target

Monte Rosa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
164.4% Upside
$11.00 Price Target
Short Interest
4.95% of Float Sold Short
Dividend Strength
News Sentiment
0.94mentions of Monte Rosa Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.92) to ($1.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.02 out of 5 stars

Medical Sector

589th out of 913 stocks

Biological Products, Except Diagnostic Industry

90th out of 153 stocks

GLUE stock logo

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

GLUE Stock Price History

GLUE Stock News Headlines

Monte Rosa Therapeutics: Q4 Earnings Insights
See More Headlines
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$3.58 per share


Free Float
Market Cap
$219.72 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Markus Warmuth M.D. (Age 52)
    President, CEO & Director
    Comp: $901.35k
  • Dr. Owen B. Wallace Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $630.68k
  • Dr. Filip Janku M.D. (Age 49)
    Ph.D., Chief Medical Officer
    Comp: $658.66k
  • Ms. Jennifer Champoux
    Chief People & Operations Officer
  • Dr. Sharon Townson Ph.D. (Age 49)
    Chief Technology Officer
  • Dr. John C. Castle Ph.D. (Age 52)
    Chief Data & Information Officer
  • Mr. Andrew Funderburk
    Senior VP and Head of IR & Strategic Finance
  • Mr. Philip Nickson J.D. (Age 45)
    Ph.D., General Counsel
  • Mr. Magnus Walter DPHIL
    Senior Vice President of Drug Discovery
  • Mr. Edmund Dunn (Age 58)
    Vice President & Corporate Controller

GLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Monte Rosa Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GLUE shares.
View GLUE analyst ratings
or view top-rated stocks.

What is Monte Rosa Therapeutics' stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Monte Rosa Therapeutics' stock. Their GLUE share price targets range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 164.4% from the stock's current price.
View analysts price targets for GLUE
or view top-rated stocks among Wall Street analysts.

How have GLUE shares performed in 2024?

Monte Rosa Therapeutics' stock was trading at $5.65 at the beginning of 2024. Since then, GLUE stock has decreased by 26.4% and is now trading at $4.16.
View the best growth stocks for 2024 here

Are investors shorting Monte Rosa Therapeutics?

Monte Rosa Therapeutics saw a decline in short interest in May. As of May 31st, there was short interest totaling 1,910,000 shares, a decline of 17.3% from the May 15th total of 2,310,000 shares. Based on an average trading volume of 185,700 shares, the short-interest ratio is currently 10.3 days. Currently, 5.0% of the shares of the company are sold short.
View Monte Rosa Therapeutics' Short Interest

When is Monte Rosa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our GLUE earnings forecast

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its earnings results on Thursday, May, 9th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.03. The company earned $1.06 million during the quarter, compared to analysts' expectations of $4.29 million.

When did Monte Rosa Therapeutics IPO?

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

Who are Monte Rosa Therapeutics' major shareholders?

Monte Rosa Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.09%), Vanguard Group Inc. (3.25%), Acadian Asset Management LLC (0.11%) and EntryPoint Capital LLC (0.03%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLUE) was last updated on 6/13/2024 by Staff

From Our Partners